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1.1 Alzheimer disease (AD)
Alzheimer disease (AD) is a cerebral neurodegenerative pathology that 
is characterized by the progressive formation of insoluble amyloid plaques 
and fibrillary tangles, first described by Alois Alzheimer nearly a century 
ago.[1] The major protein component of the plaques is the amyloid-b
peptides (Ab), and the tangles are composed of filaments of the
microtubule-associated protein tau.
Although AD is the most common cause of dementia in western 
industrialized countries, up to now, there is no approved causal treatment. 
The available symptomatic treatments or disease modifiers provide only 
limited benefits to the affected people. The approved drugs, such as Vitamin 
E or AChE inhibitors, slow down, but do not stop the disease 
progression.[2] Thus, a growing need exists for new effective therapies with 
a specific mode of action, which allows to control the onset and the 
progression of the disease. Over the last decade, great attention has been 
paid to the cascade of physiological events that contribute or accompany 
AD.[3-5] 
Many pathological analysis at cytological and biochemical levels,
reveals that, in AD, fibrillar forms of Ab densely deposit forming neuritic
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plaques in cerebral and midbrain regions associated with cognition and 
memory. Moreover, it has been demonstrated that fibrillary tangles, also 
localized in the brain regions critical to higher brain function, were found to 
be characterized by the filamentous form of the hyperphosphorylated tau
protein. Tau hyperphosphorylation renders insoluble this otherwise highly 
soluble cytosolic protein, and this modification seems to be essential for the 
pathogenic profile of these tangles. Interestingly, tau-containing 
neurofibrillary tangles occur in a number of other, uncommon
neurodegenerative diseases, while the amyloid containing neuritic plaques 
are unique to AD.
A major point of debate in the last recent years was if these lesions are 
causative or simply “tombstones” or markers of regions that have 
degenerated due to unknown pathogenic events. After the identification of 
genes associated with AD, it has been unequivocally demonstrated that 
alterations in the proteolytic processing that produces Ab protein can cause 
the disease. As a consequence, Ab is either the molecular culprit or an 
intimately linked epiphenomenon, in either event, inhibiting the responsible 
proteases would be a fruitful strategy to deal with AD.
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The amyloid hypothesis.
The above reported observations embody the amyloid hypothesis of AD 
pathogenesis, which states that production and deposition of Ab fibrils leads 
to neuronal cell death and eventually to the clinical onset and progression of 
AD (Figure 1).
Figure 1. The amyloid hypothesis of AD pathogenesis.
In the recent years, key pieces in the puzzle of AD have been falling 
into place. Particularly, the secretases responsible of the APP processing are 
no longer completely mysterious and it is generally accepted that, the b-
amyloid precursor protein (APP) is cleaved by two proteases to generate the 
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40/42 amino acid long amyloid-b peptides (Ab). The increased Ab
formation results in extracellular amyloid plaques deposition and it is 
accompanied by the intracellular formation of neurofibrillary tangles in the 
brain.[5,6] The neurotoxicity associated with the Ab•oligomerisation is 
supposed to cause neuronal death, brain inflammation, and finally AD.[7] 
The APP is processed via the major a- or the minor b-secretase pathway; 
both produce fragments further processed by g-secretase.[8] 
Differently from the non pathogenic products of a/g-secretase pathway, 
the b/g-secretase pathway produces pathogenic Ab peptides. 
Certainly, an understanding of the mechanism of g-secretase specificity 
may suggest strategies to selectively decrease the production of the more
deleterious Ab peptide. Even though g-secretase is an aspartyl protease, its 
peculiar active site topology makes this enzyme less tractable with respect 
to other common proteases. Indeed, the two key aspartates crucial for 
proteolytic activity seems to be embedded in the membrane, and other 
members of what is likely to be a larger g-secretase complex have not been 
yet identified. For all these reasons, the X-ray structure of this secretase is 
far to be detected soon. Thus, only the information derived from affinity 
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labelling with transition-state analogue inhibitors and site directed
mutagenesis may be used to characterize its active site. 
Alternative processing of APP by a-secretase precludes Ab production, 
since this proteolysis occurs within the Ab sequence at Lys686-Leu689
generating non pathogenic peptides. Two missense mutations in APP near
the a-secretease cleavage site, cause disease and an increased Ab
production, as more APP is shunted into the b-secretase pathway. In 
addition, evidence suggests that a-APPs may be neuroprotective with 
general beneficial effects on learning and cognition, so augmenting a-
secretase processing of APP may be a valuable strategy in treating AD.
After the demonstration that b-secretase (BACE-1), a member of the 
pepsin family of aspartyl proteases, is the rate-limiting enzyme in the 
production of Ab,[9] and that its genetic depletion in mice abolishes the b-
amyloid formation without major side effects,[10] BACE-1 has emerged as 
a leading target for the therapeutic treatment of Alzheimer disease.[11] 
Recently, BACE-1 was shown to control the myelination of the peripheral 
nerves in the late foetal development, the relevance of this finding to 
chronic treatment of adults will have to be considered.[12] 
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1.2 The current state of art on BACE-1
So far, two b-secretases are known, BACE-1 and BACE-2, and they 
exhibit 52% amino acid sequence identity and 68% similarity and cleave 
APP and short peptides in a very similar manner. Interestingly, BACE-2 is 
mainly expressed in highly vascularized systemic tissues and not well in the 
brain, with the implication that it has not a key role in the AD plaque 
formation. Furthermore, while BACE-1 preferentially cleaves APP on the 
lumenal/extracellular side at approximately 30 residues from the 
transmembrane domain at the sequence EVKM*DAEF (the asterisk denotes 
the cleavage site), BACE-2 makes an additional proteolysis in the middle of 
the Ab region, suggesting that BACE-2 might limit the production of 
pathogenic forms of Ab. If such were the case, the achievement of a 
selective inhibition of BACE-1, leaving BACE-2 active, is of great interest.
Up to now, several X-ray structures of BACE-1 (hereinafter "BACE") 
have been reported, either in the apo form (PDB codes: 1SGZ and 1W50), 
either in complex with large-size peptidomimetic ligands (1FKN, 1M4H, 
1XN2, 1XN3, 1XS7, 2F3E, 1YM2, 1YM4, 2B8L, 2B8V and 2FDP), or with 
rather small inhibitors (1W51, 1TQF, 2G94). An important advance in the 
elucidation of the inhibitor-BACE recognition process has been provided by 
Chapter I - Introduction
- 8 -
the 1W51 structure, where the enzyme has been cocrystallized with the 
inhibitor 1.[13] Figure 2 highlights the main interactions between 1 and the 
BACE-1 enzyme.
Figure 2. Schematic representation of the main interactions of 1 with the 
BACE catalytic site.
A detailed comparison of the available X-ray structures suggests that 
BACE can assume at least two major conformations mainly differing in the 
FLAP region, which can adopt an open and a closed conformation in the 
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ligand free and ligand bound enzyme, respectively. Thanks to the 
availability of all these structures, great strides in the development of new 
BACE inhibitors have been made by both academic and industrial research 
groups. As a result, Vertex, and recently Wyeth, reported new inhibitors 
bound to BACE with the flap open conformation.[14]
Many noncleavable transition state isosters were designed as new 
inhibitors on the basis of initial kinetics and substrate specificity data.[15] 
Most of these peptide ananlogues mimic the scissile amide bond of the 
endogenous substrates.[16,17] The hydroxyethylenes derivates, such as 
OM99-2 and OM00-3, represented the first class of highly potent BACE 
inhibitors.[15], The employment of the statine moiety led to the 
peptidomimetic compound 2 (IC50 = 20 nM), which features non peptidic 
portions at both C- and N-termini.[19] In the effort to reduce the peptidic 
character of the first inhibitors, several hydroxyethylamine-containing 
compounds were investigated as new BACE inhibitors. Among them, 
inhibitors 3 and 4 are of particular interest for their low nanomolar activity 
(IC50 = 1 and 1.4 nM, respectively) and for the originality of their 
structures, being the secondary amine of HEA arranged in a six-membered 
cycle.[20] With the aim of achieving selectivity for BACE over the other 
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aspartic proteases, a sulphonylamide group has been introduced in an HEA 
derivative leading to compound 6.[21] Recently, high BACE-1 selective 
compounds, (e.g. compound 5, IC50 = 4 nM) featuring a Y(CH2NH) 
reduced amide bond, were reported by Coburn et al.[22]
1.3 Future Perspective via new Computational Methodologies
Despite this considerable progress, it is worth noting that the majority of 
the reported peptidomimetics with low nanomolar activity in BACE-1 
enzymatic assays are poorly active in cell-based assays because of the 
limited penetration across the cell membranes. Thus, non-peptidic inhibitors 
with a lower molecular weight, suitable for oral delivery and transport 
through the cell membranes and the blood-brain barrier are still in great 
demand. In spite of all efforts made by the pharmaceutical companies and 
academic groups, non-peptidic leads for BACE inhibition are still few.[23] 
Thus, BACE turns out to be a structurally challenging target having on one 
hand multiple sites for effective binding and, on the other hand, an high 
homology with other aspartyl proteases such as cathepsin D, pepsin or renin. 
Currently, medicinal chemists can choose among a number of novel 
approaches for drug discovery such as high-throughput in vitro screening, 
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combinatorial chemistry, focused library or pharmacophore-based and/or 
target structure-based virtual screening (VS), being the latter two 
approaches increasingly used having the advantage to avoid long and
expensive experimental efforts. However, the pharmacophore-based VS is 
exclusively possible when a trustworthy pharmacophore model exists, while 
the structure-based VS needs the design of a proper protocol as it is well-
known that several features, as the charge state of potential-interactive 
residues, the protein conformations (apo and ligand bound), the docking 
methods and the scoring functions can all deeply affect the success rate. In 
this regard, the works of Polgàr and Keserü[24] are particularly helpful, as 
the influence of protonation state of catalytic Asp residues of BACE (D32 
and D228) as well as the enzyme conformations were investigated in a 
comparative VS. From these studies, it emerges that the monoprotonated 
form (D228-, D32) of the BACE catalytic site gave better enrichment factor 
compared to the default protonation state (D32 and D228 deprotonated), and 
ligands can find proper poses easier in a ligand-bound structure (FLAP 
closed), than in the unbound form (FLAP open). Interestingly, the 
introduction of pharmacophore constraints in the docking calculations 
improved enrichment factors for both structures (bound and unbound), 
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reducing ligands false positive poses and increasing the inactive drop-out 
rate.
In structure-based VS, a 3-D pharmacophore model can be used either 
to constrict the number of the possible ligands poses either to pre-screen 
compounds databases, both helping to pursue a more accurate and saving-
time simulations. The pharmacophore constraints used in the study of Polgàr 
and Keserü were retrieved from a patent document, where a congeneric 
series of BACE-1 inhibitors were presented.[14]
Here, with the aim to extend our understanding of inhibitors binding at 
the BACE-1 catalytic site and to provide an exhaustive structure-based 
pharmacophore model, the most active and selective (whenever it was 
possible) compound for each class of BACE inhibitors (see above) (2-6) 
was selected and subjected to an ensemble molecular docking process into 
five BACE X-ray structures. The superimposition of the calculated 
bioactive conformations of these inhibitors allowed us to capture both the 
common geometric and electronic features essential for the ligand 
recognition and the enzyme inhibition. Furthermore, in order to achieve 
BACE-1 selective inhibition, a comparison of the X-ray structures of 
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BACE-1 and the cathepsin D was made to better understand the structural 
and chemical differences in their respective catalytic sites.
The elucidation of the different binding modes of the diverse ligands on 
one hand, and the development of a pharmacophore model on the other, are 
intended to extend our knowledge in the BACE field furnishing a support 
for pharmacophore- and/or structure-based VS techniques and a source for 
the optimization of the screened compounds as well as of the already known 
leads. Moreover, the proposed pharmacophore hypothesis can be of help in 
the common target-based and ligand-base drug design approaches as well as 
in the setting of a focused-library of BACE inhibitors.
Chapter I - Introduction
- 14 -
Chart 1. Chemical structures of docked compounds.
N
H
N
H2+OH
OCH3
O
N
O
 
1
(IC50 = 200 nM)
HO
N
H
O
F
F
H
N
O
N
H
O
CO2H
CO2H
OH
*
2
(IC50 = 20 nM)
F
CH3
H
N
O
N
S
O O
H
N
O
N
H2+
H
N
O
 
5
(IC50 = 4 nM)
N
N
O
O
N
H OH
N
H2+
NO
F
F
3
(IC50 = 1 nM)
O
N
H OH
N
H2+
NO
F
F
O
N
MeO
4
(IC50 = 1.4 nM)
N
S
O O
H
N
O
H2+
N
OH
6
(IC50 = 35 nM)
Chapter II – Results and Discussion
- 15 -
CHAPTER II
RESULTS AND DISCUSSION
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2.1 X-ray Structures Selection for the Ensemble Docking Studies
Even today, a major hurdle for a successful molecular docking is the 
protein flexibility. At the present time, many effective methods are available 
for docking a flexible ligand into a rigid protein, while docking calculations 
including target flexibility still remain problematic, both in terms of 
computational time and efficiency. In this respect, BACE shows the type of 
flexibility that can pose challenging problems in docking simulations as the 
enzyme is known to undergo a massive rearrangement of the FLAP region 
(residues 68-74) during association with ligands and a certain mobility is 
expected for the “10S loop” (residues 9-14). To the best of our knowledge, 
no docking program, that attempts to include wide flexibility of the protein, 
has been extensively validated so far. Fortunately, in the case of BACE, 
numerous crystallographic structures exist enabling us to use an ensemble of 
enzyme conformations for our docking calculations. Docking a ligand into a 
battery of binding pockets is a strategy to deal with the protein flexibility, 
although it is still far from perfection.
A comparative structural analysis of all available BACE structures 
revealed that the FLAP region is always in the closed conformation 
whenever an inhibitor, either peptidomimetic or non-peptidomimetic, is 
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bound. Because ligands 1-6 are substrate analogues that interact with the 
FLAP-closed form of BACE, we limited our studies to all BACE structures 
with a FLAP closed conformation (PDB codes: 1FKN, 1M4H, 1TQF, 
1XN2, 1XN3, 1XS7, 1YM2, 1YM4, 2B8L, 2B8V, 2FDP, 2G94, 2F3E, 
2F3F). With the aim of reducing the BACE structure redundancy, only the 
most divergent structures were considered for our docking calculations.
To assess the differences among the BACE structures, they were 
superimposed on the alpha carbon atoms (Ca) using 1W51 structure as
reference. Interestingly, the FLAP closed conformations are all surprisingly 
similar regardless of the inhibitor type bound, while some differences came 
out in the side chains conformations of few residues, with the most notable 
one residing in Q73 (Figure 3). Additionally, some expected flexibility was 
also found in various residues lining the binding site cleft such as R128, 
T231, D307 and D235.
From the comparative analysis of BACE X-ray structures, it clearly 
emerges that the “10S loop”, a short loop located between two strands at the 
base of the S3 subpocket, shows mainly three low-energy conformations, an 
open (1FKN, 1XN3, 1XN2, 1XS7, 1YM2, 1M4H, 2F3F, 2G94) a closed 
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(1W51, 1FDP, 2B8L, 2B8V, 1YM4, 2F3E) and an outlier conformation 
(1TQF) (Figure 3).
In view of the capability of “10S loop” in affecting the shape of the S3 
subpocket (S3sp) and thus the ligand binding,[25] the inclusion of such 
structural variability in a docking study becomes of fundamental 
importance. Consequently, 1FKN,[26] 1W51,[13] and 1TQF,[27] were 
chosen for our docking experiments since they cover the experimentally 
observed motions of the “10S loop” as well as of some residues in the 
catalytic site such as Q73, R128, R307, R235, and T231. Two additional 
structures were considered (1XN3 and 2G94)[28,29] so as to include 
additional conformers of Q73 and R235 residues. As a result, each ligand 
was docked in a total of five BACE structures (1FKN, 1W51,1TQF, 2G94, 
1XN3).
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Figure 3. Cartoon representation of the BACE X-ray structures used for the 
ensemble-docking study (1W51, 1FKN, 1TQF, 1XN3, 2G94 are in pink, green, cyan, 
yellow and orange, respectively) with 1 shown as grey sticks and transparent grey 
spheres; hydrogen atoms are omitted for clarity reason. The most flexible residues, 
emerged from the BACE X-ray structures superposition, are represented in stick 
mode and coloured according to the BACE structures colour code.
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2.2 Assessment of the Docking Program
Although AutoDock program is the most widely used docking 
program[30] and has been extensively validated, it is well-known that each 
docking algorithm performs better for certain protein systems than for 
others, thus the reliability of a docking program towards the target of 
interest has always to be assessed. Furthermore, testing a program by 
docking a ligand into its native protein is intrinsically biased because the 
protein has already changed its shape to better accommodate the ligand and 
this unavoidably affects positively the docking results. Here, with the aim to 
accurately evaluate the program performances on the studied system, a 
cross-docking experiment of 1 in its native enzyme (1W51) and in four non-
native enzyme conformations (1FKN,1TQF, 2G94 and 1XN3) was 
conducted. It is generally accepted that, a successful docking result 
reproduces the crystallographic conformation of a ligand in the complex 
structure within ~2 Å of RMSD on all ligand atoms, and that the first-
ranked docked conformation (herein referred as ranking conformation) is 
the preferable one. On the other hand, from our experience, in the case of 
Autodock program, the lowest energy conformation of the most populated 
cluster (herein referred as cluster conformation) has to be taken into account 
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as well. In the case of BACE, in two complexes, 1W51 and 2G94, the 
conformation calculated by AutoDock with the lowest free energy of 
binding belongs to the most populated cluster, thus, no ambiguity exists for 
the selection of the “best” binding pose. Autodock program well reproduced 
the experimental binding mode of 1 (Figure 2) both in native (1W51) and 
non native (2G94) enzyme structure, with a RMSD values of 0.4 and 0.6 Å, 
respectively. For the other three enzyme structures, good results were 
obtained considering the cluster conformations (0.59 Å for both 1FKN and
1TQF, and 1.20 Å for 1XN3) while the accuracy in reproducing the X-ray 
conformation lowered when the ranking conformation was considered only 
(2.9 Å for 1FKN, 3.4 Å for 1TQF and 2.8 Å for 1XN3).
In order to make the test independent from the single ligand used (1), we 
carried out an additional cross-docking experiment using the inhibitor 
referred as compound 5 in the paper of Ghosh et al. (complex PDB code: 
2G94).[28] The experimental binding conformation of Ghosh ligand was 
well reproduced in four out of five BACE structures when either the ranking 
or the cluster conformation is considered. Specifically, in 1TQF and in the 
native 2G94 BACE structures, AutoDock perfectly predicted the 
experimental pose (RMSD value of 1.45 and 1.12 Å, respectively) and 
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provided one unambiguous solution since the ranking conformation belongs 
to the most populated cluster. In 1FKN and 1W51 structures, the ranking 
conformation well reproduces the correct pose having an RMDS value of 
1.82 and 1.46 Å, respectively. Only in the case of 1XN3, AutoDock did not 
exactly reproduce the X-ray conformation of the inhibitor (RMSD value of 
3.10 Å). After a visual inspection of the docking results, it clearly emerged 
that the cluster conformation places the ligand in a very similar way to the 
X-ray conformation apart from the diazole branch that fills the S2 region in 
the place of the sulfonyl moiety. This exchange might be due to the different 
conformation of Arg235 with respect to the others X-ray BACE structures. 
All in all, our test experiments clearly proves that Autodock program can be 
successfully applied to BACE-1 field, although whenever the ranking 
conformation does not correspond to the cluster one, both solutions have to 
be taken in consideration. The final choice between the ranking and the 
cluster conformations will be governed by their coherency with 
experimental data, when available (e.g. SARs).
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2.3 Docking Results
Docking of 2. Due to the undetermined absolute stereochemistry of the 
carbon atom attached to the biphenyl ring of compound 2[19] both 
stereoisomers were subjected to docking calculations.
Docking of 2 with the (R) absolute stereochemistry revealed that in four 
out of five calculations (1TQF, 1W51, 1XN3 and 2G94) comparable results 
were found for all the predicted ranking conformations. Using as receptor 
1FKN, docking of 2 did not succeed in predicting a plausible binding mode, 
therefore it was omitted from the comparison. As depicted in Figure 4, the 
(S) statine isoster places the hydroxyl group in between the catalytic dyad 
allowing the simultaneous interaction with D32 and D228 as previously 
observed in other X-ray complexes (e.g. 1FKN).
Chapter II – Results and Discussion
- 24 -
Figure 4. Binding mode of compound 2 (green) into BACE catalytic site 
represented as Connolly surface. The ligand and the interacting residues are 
shown in stick representation and coloured by atom type, while the FLAP 
region is represented as cartoon. Hydrogen bonds are represented with dashed 
black lines. All nonpolar hydrogens were removed for clarity.
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The difluorobenzyl moiety of 2 (P1) occupies the aromatic pocket S1, 
analogously to the corresponding benzyl group of 1. Noteworthy, due to the 
withdrawing property of the fluorine atoms present on the aromatic system 
of 2, the charge transfer interactions of the P1 branch in 2 with the Y71, 
W108 and P115 aromatic rings are expected to be stronger with respect to 
those observed for compound 1. Analogously to 1, the calculated binding 
mode preserves the H-bond with G34 backbone CO, while two additional 
H-bonds with T72 and T231 side chains are present (Figure 4).
Unfortunately, a direct comparison between the potency of 2 (IC50 = 20 
nM) and 1 (IC50 = 200 nM) is not meaningful, this is due to the different 
biological assays. Differently from 1, compound 2 features an isopropyl 
group (P1’) which establishes hydrophobic contacts with I226 and V332 
side chains (S1’ pocket) while the biphenyl moiety deepens into a narrow 
passage (S3sp) mainly formed by two glycines (G13 and G230). An 
interesting feature of 2, which certainly contributes to its great potency 
(IC50 = 20 nM), is the aminocyclohexanedicarboxylate moiety (P2’), which 
was inserted to mimic the C-termini of the first known peptidic 
inhibitors.[15,18] Indeed, docking results confirm that this P2’ moiety 
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entirely fills the S2’ hydrophobic pocket with both the carboxylate groups 
engaging a charged-reinforced H-bond with the guanidine group of R128.
Docking of 2 with biphenyl unit attached in the (S) configuration gave 
for three out of five docking calculations (1FKN, 1XN3 and 2G94) a 
slightly different binding conformation in comparison to that found for the 
(R) isomer. Indeed, the main interactions with the enzyme are well 
conserved for this isomer while some differences come out for the N-
terminal moiety (P3 branch). Here, the biphenyl group points into the S3sp, 
similarly to the (R) isomer, while the hydroxyl function due to its (S) 
stereochemistry is now incapable to interact with T231. Although it is 
unknown which is the most active diastereoisomer, it has been reported that 
one isomer is 100 fold more active than the other.[19] Our docking results 
do not clearly discriminate between the two analyzed isomers. Nevertheless, 
the low convergence of docking results for the (S)-isomer allows us to 
hypothesize a weaker binding to BACE if compared to the (R)-isomer.
However, the proposed binding modes are in alignment with the 
available SARs data.[19] Indeed, analogues of 2, featuring non acidic 
aminocyclohexanedicarboxylate derivatives, do not interact with R128, this 
results in a loss of activity.[19] 
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Furthermore, the replacement of the aminocyclohexanedicarboxylic 
moiety by 4-aminomethylbenzoic acid, presenting only one acidic function, 
caused a 10-fold loss of activity thus demonstrating the contribution of both 
acidic groups for the enzyme binding. Interestingly, the 
aminocyclohexanedicarboxylic methylester derivative displays only a 10 
fold decrease in the inhibitory activity. These data are in accordance with 
our results, which place the aminocyclohexanedicarboxylic near to R128, 
where the carbonyl of the methyl ester forms an H-bond with the guanidine 
side chain.
Docking of 3 and 4. The binding pose of 3 does not substantially change 
when different enzyme structures are used and basically resembles the 
binding position found for 1 and 2. As depicted in Figure 5a, the hydroxyl 
group of the HEA core H-bonds with D32, while the protonated secondary 
amine, which differs from 1 by the locked conformation of the 6-membered 
ring. It engages a salt bridge with D228 and H-bonds with G34. 
Interestingly, all HEA derivatives feature an unusual stereochemistry at the 
secondary alcohol (R absolute configuration). A secondary amine in the 
HEA derivatives causes the interaction with D228, which would be lost by 
the inversion of the stereochemistry at the secondary alcohol. The benzyl 
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ring (P2’) is stacked in between the Y198 and Y71 residues (S2’ pocket), 
while the ligand amide group H-bonds with G230 and Q73 backbones. 
Analogously to 2, the difluorobenzyl branch (P1) fills the S1 pocket shaped 
by Y71, F108 and W115 residues (Figure 5a).
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Figure 5. Binding modes of compound 3 (a) and 4 (b) into 
BACE catalytic site.
Chapter II – Results and Discussion
- 30 -
While the above-described interactions are conserved in all five BACE 
structures, an ambiguity was encountered for the relative position of the 
imidazolidinone moiety. Ligand docking into 1W51 and 1XN3 structures 
placed the imidazolidinone so as to allow the carbonyl group to H-bond 
with T232 backbone, the benzyl group (P2) to establish a cation-p
interaction with the guanidine group of R235 and the N-alkyl substituent to 
thread into the narrow S3 subpocket (S3sp) (Figure 5a). However, the ligand 
docking into 1FKN and 1TQF structures, placed the imidazolidinone ring so 
that the phenyl ring pointed to the S3sp, while the alkyl chain pointed out of 
the enzyme. In this case, ensemble docking leads to two comparable but not 
equal conformations. A subsequent analysis of BACE structures suggests 
that the different conformations of the R235 side chain are mainly 
responsible for the divergent results. More precisely, in 1W51 and 1XN3 
structures, the R235 side chain is optimally oriented to engage a cation-p
interaction with the phenyl ring of 3 (Figure 5a), while in 1FKN and 1TQF 
structures, the R235 guanidine group partially occludes the catalytic site so 
as to prevent the placement of the phenyl group. Although both ligand 
conformations are feasible, the orientation of the N-alkyl substituent into the 
S3sp and the benzyl moiety towards the external part of the enzyme 
Chapter II – Results and Discussion
- 31 -
maximizes the interaction with the protein by allowing the formation of a H-
bond with T232 and a cation-p interaction with R235. Further support for 
this hypothesis is provided by recent X-ray studies outlining the importance 
of the interactions with T232 and R235.[31]
Similarly to 3, the HEA isoster in 4 well interacts with both the catalytic 
aspartates as well as with G34 (Figure 5b). The benzyl and difluorobenzyl 
moieties of the ligand optimally fill S2’ and the S1 pockets, respectively, 
while the isophthalamide group lies in the S2 open region with one of the 
two amide functions H-bonding with G230 and Q73. Interestingly, the 
methoxymethyl substituent of the pyrrolidine protrudes above the S3sp, 
where polar interactions occur with R307 and T232 side chains. The high 
potencies of 3 and 4 (IC50 = 1 nM, IC50 = 1.4 nM, respectively) suggest 
that T232, R235 and R307 are further points of ligand attachment 
strengthening the inhibitor binding.
Docking of 5 and 6. Ensemble docking experiments on 5 and 6 showed for 
both of them convergence of results. In fact, all the docking calculations 
apart from one (1W51) detected a single solution which is at the same time 
the ranking and cluster conformation.
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The protonated nitrogen of 5 was found to interact with D228 while the 
isobutylamide branch (P2’) engages H-bonds with T72 and G34 placing the 
alkyl chain into the hydrophobic S2’ pocket (Figure 6a). The n-propyl 
branch (P1’) lies in S1’ pocket shaped by hydrophobic aminoacids such as 
I226, V332 and Y198. The benzyl group (P1) is placed into the aromatic 
cage S1 with the adjacent amide group forming two H-bonds with G230 and 
Q73. Comparing the binding modes of the docked ligands, we noticed that 
H-bonds with G230, T72 or Q73 backbones are frequently present and this 
seems to be important for high BACE inhibitory activity.[32] Interestingly, 
in all the five BACE structures used for the ensemble docking, the N-methyl 
methylsulfonamide group (P2) was found in a polar region among N233, 
S325 and R235, mostly interacting with the latter residue. The proposed 
location of the sulfonamide function is in line with the recently reported X-
ray structures of BACE complexed with some sulfonamide-containing 
ligands.[21,27,29,32]
The difluorobenzyl branch deepens inside the narrow channel in the 
S3sp engaging a T-shape interaction with Tyr14 (Figure 6a). It is interesting 
to note that this channel constitutes the access to an additional small pocket 
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lined by hydrophobic residues (L152, L154, V31 and Y14) and up to date 
no inhibitor has entirely filled this newly identified pocket.
The hydrophobic interactions of the n-propyl branch (P1’) in the S1’ 
pocket are supported by SAR data which show a slight decrease of activity 
for the ethyl and/or methyl (P1’) substituent.[22] Furthermore, additional 
SARs suggest that an H-bond donor on P2’ substituent can be important for 
BACE activity and this is in agreement with our finding of an H-bond 
interaction between the isobutylamide branch and the G34 backbone.
Due to the structural similarity, compound 6 docked in a mode similar 
to 5. Nevertheless, being 6 an HEA derivate, it contacts both D32 and D228,
as described for all the other HEA derivates. While the benzyl group (P1) 
deepens into the S1 pocket, the sulfonamide group engages an electrostatic
interaction with R235 (Figure 6b).
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Figure 6. Binding modes of compound 5 (a) and 6 (b) into 
BACE catalytic site.
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The two cyclopropyl branches of 6 fit in the hydrophobic S1’ pocket 
and S3sp, respectively. Despite the structural similarity, compounds 5 and 6
show different activities (IC50 = 4 and 35 nM, respectively). According to 
our docking results, this difference in potency has to be ascribed to the 
additional interactions established by 5, which occupies S3sp, S1’ and S2’ 
pocket, while 6 just partially occupies the S3sp and S1’pocket and does not 
fill the S2’ pocket at all.
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2.4 Pharmacophore Fingerprints and Guidelines for Drug Design
The superimposition of the calculated bioactive conformations of 
inhibitors 1-6 (Figure 7a) allowed us to capture both the common geometric 
and electronic features essential for the ligand recognition and the enzyme 
inhibition. From the analysis of the interactions established between the 
ligands and the enzyme, it is apparent that both polar and hydrophobic 
interactions are equally important in the inhibitor-enzyme recognition 
process.
Despite the structural diversity, compounds 1-6 are linked by five highly 
conserved pharmacophoric points (blue spheres in Figure 7b and 7c): three 
H-bond donors (D1, D2 and D3), one acceptor (A4) and one hydrophobic 
centre (H5). All compounds, with the exception of 5, feature an interaction 
point with D32 (D1) and with the other catalytic aspartate (D228) through 
the D2 point. This observation confirms the importance of the interaction 
with the two catalytic aspartates of the binding site for an effective enzyme 
inhibition. Furthermore, all compounds, apart from 2, present the D2 point. 
This highlights the convenient insertion of a protonable amine in this 
position to achieve a simultaneous interaction with D228 and G34 residues. 
As shown in Figure 7c, the D3 point donates an H-bond to G230 backbone 
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CO while the H-bond acceptor A4 interacts with either T72 or Q73 
backbone NHs. It is noteworthy how these two latter points (D3 and A4) 
represent an ancestral inheritance of the endogenous ligands of BACE 
where these points are normally filled by an amide moiety of the peptidic 
backbone.
Despite the relevance of such polar features, the hydrophobic point H5, 
constantly present in 1-6, underlines the essential role of an hydrophobic 
group in this position, interacting with the S1 pocket residues Y71, W108 
and F115. (Figure 7c).
The frequent occurrence of D1, D2, D3, A4 and H5 pharmacophoric 
points in the analysed compound set (Table 1) suggests that these are the 
indispensable features for ligand recognition. Unfortunately these 
interactions do not offer the key to selective BACE inhibition. This is due to 
the conservation of the majority of their corresponding interacting residues 
in other proteases such as cathepsin D as discussed hereafter.
From our docking results, four additional pharmacophore points, 
represented as cyan spheres in Figure 7b and 7c, emerge. They are mostly 
hydrophobic (H6, H7 and H9), with the exception of one, that can be either 
hydrophobic or a polar (H/A8).
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Figure 7. a) Overlay of bioactive conformations of compounds 1-6 on the experimentally 
determined bound conformation of 1. The pharmacophoric points are colour coded as 
conservative (blue) or additional (cyan). The non polar hydrogens are omitted for clarity. 
The letter “A” corresponds to an H-bond acceptor group, “D” to an H-bond donor, while 
“H” to an hydrophobic group. “A/H” means that an H-bond acceptor or an hydrophobic 
group is tolerated. b) Tridimensional representation of the distances between the identified 
pharmacophoric points. The distances are reported in Å and represent the minimum and the 
maximum value found in the proposed bioactive conformations of 1-6. The distances were 
calculated considering the nitrogen and oxygen atoms of the H-bond acceptor and donor 
groups, the sulphur atom of the sulphonamide function, the centroids of the aromatic rings, 
the centre of mass of the alkyl and cycloalkyl groups. c) Mapping of the pharmacophoric 
points into the BACE catalytic site represented as Connolly surface. Interactions between 
the pharmacophoric points and some BACE residues are highlighted by black dashed lines.
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The H6 point represents an hydrophobic feature able to reach the S2’ 
pocket (Figure 7c). The structural variability of this feature (Figure 7a) 
demonstrates that, although an aromatic substituent in H6 is not mandatory 
(see compounds 2 and 5), an hydrophobic group is required due to the 
nonpolar character of the S2’ pocket. It is worth noting that in all analysed 
compounds, only 2 features the optimally functionalized H6 point having 
two carboxyl groups that establish a double salt bridge with R128. Such an 
interaction is particularly interesting being R128 an unique feature of BACE 
enzyme. In order to achieve a better pharmacokinetic profile preserving a 
good inhibitory potency, the acidic functions present in the H6 point could 
be methylated not preventing the ability to H-bond with R128.
The additional point H7 finds place in the hydrophobic S1’ pocket 
(I226, V332 and Y198) where, due to its limited dimension, only an alkyl or 
cycloalkyl chain with at maximum three carbon atoms, seems to be 
tolerated. This position was recently employed to achieve selective BACE 
inhibition and should be investigated further.[33]
Another pharmacophoric point, which may be exploited to achieve 
BACE-selectivity, is represented by the H/A8 point, which is located in the 
S2 open region and can be either hydrophobic or polar. An H-bond acceptor 
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in this position, such as a sulfonamide (compounds 5 and 6), or an 
hydrophobic phenyl ring (compound 3) can interact with the surrounding 
residues such as N233, R235 and S325. These three residues are peculiar to 
BACE in comparison to other proteases, thus this interaction is expected to 
have an important role in the BACE selectivity. Our observation is in 
accordance with the recently reported X-ray analysis of the co-crystallized 
complexes of some selective BACE inhibitors featuring a sulfonamide 
group as H/A8 point.[27,29]
After the superposition of all compounds in their predicted binding 
poses, it clearly emerges a different sized branch as H9 point indicating that 
aliphatic, as well as aromatic branches are well tolerated in the S3sp. The 
extension of this pocket mainly depends on the conformation of the 10S 
loop, but it has to be pointed out that among all analysed compounds, only
inhibitor 5 goes across the S3sp, reaching with its aromatic system the inner 
hydrophobic pocket made by L152, L154, Vl31 and Y14 residues. In the 
design of new BACE inhibitors, this cavity should be further explored, as 
demonstrated for the renin inhibitor aliskiren.[34] Comparing the BACE 
and renin cavities, we noticed that they have chemical and structural 
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differences, which offer additional chances to improve the inhibitor 
selectivity.
Table 1. Pharmacophoric points present in ligands 1-6.
Compounds Points
1 D1-D2-D3-A4-H5-H6-H9
2 D1-H5-H6-H7-H9
3 D1-D2-D3-A4-H5-H6-H/A8-H9
4 D1-D2-D3-A4-H5-H6
5 D2-D3-A4-H5-H6-H7-H/A8-H9
6 D1-D2-D3-A4-H5-H7-H/A8-H9
The compounds 1-6 are characterized by five to eight identified 
pharmacophoric points (Table 1); appropriate chemical modifications can 
result in more potent analogues. For instance, the BACE binding affinity of 
compound 5 may be improved by the addition of an hydroxyl group on the 
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carbon of the Y(CH2NH) reduced amide bond so as to present the D1 point 
and complete the nine-point pharmacophore.
Regarding compound 1, the substitution of the n-propyl chain with a 
benzyl moiety may optimize the interactions with the BACE S3sp and the 
addition of an H-bond acceptor in position 2 on the isophthalamide group
such as a sulfonate or carbonyl group may provide the basis for BACE 
selectivity.
So far, only one pharmacophore model derived from a congeneric series 
of BACE inhibitors has been disclosed via a patent application by 
Vertex.[14] The authors proposed that the flap is shifted and stabilised in an 
open conformation in the presence of their inhibitors.
Comparing the Vertex pharmacophore model with ours, we found that 
the two models are rather similar regarding the pharmacophoric points 
interacting with the residues unaffected by the flap movement (Table 2). 
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Table2. Distances (Å) between the pharmacophoric points and the BACE 
interacting residues. 
Pharmacophoric Points Interacting Residues Distances[a]
D1 D32 4.9
D2 G34D228
3.7
4.5
D3 G230 4.4
A4 Q73 4.5
H5 Y71P108
5.4
8.9
H6 Y71Y198
5.4
8.1
H7 I226V332
6.0
6.4
H/A8 R235N233
5.6
5.3
H9 G11G230
5.1
4.5
[a] The distances were calculated considering the pharmacophoric points and each 
Cb of the corresponding residues, Ca were taken into account for glycine residues. 
As pharmacophoric points the nitrogen and oxygen atoms of the H-bond acceptor 
and donor groups, the sulphur atom of the sulphonamide function, the centroids of 
the aromatic rings, the centre of mass of the alkyl and cycloalkyl groups, were 
considered.
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In particular, the Vertex model shares a pattern of three H-bond donors, 
and two hydrophobic points corresponding to D1, D2 and D3 and H5 and 
H6 in our model. Despite the general coherency of the chemical features of 
these points in both pharmacophoric models, the reported distances between 
them diverge to a large extent. For instance, in our model, the distance 
between D1 and D2 and D1 and D3 is maximum 2.9 and 3.8 Å respectively, 
(see Figure 7b) while in the Vertex model both range from 4 to 5 Å. 
Moreover, the D1-H6 distance is calculated as a range of 4.2-7.8 Å in our 
pharmacophore model and this value is very low in comparison to the 
minimum distance of 8 Å reported for the corresponding points in the 
Vertex model (HB-1 and HPB-3, respectively). This discrepancy may be 
due to the fact that Vertex model places the HPB-3 point in a different 
pocket of the S2’ region.
The discrepancies found between the two pharmacophoric models can 
be assigned to the different compounds used for model generation. The 
Vertex pharmacophore derived from a congeneric series based on a 
piperazine scaffold which are thought to stabilize the flap in an open 
conformation. Consequently, in their pharmacophoric model, an additional 
hydrophobic point referred as HPB-2 is involved in the interactions with the 
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flap pocket (W76, F108, F109, W115 and I102). Here, we have used BACE 
with the flap in a closed conformation, thus this pocket is no longer present. 
Consequently the HPB-2 point has to be considered a typical feature of the 
open flap pharmacophore model.
With respect to the Vertex model, our model offers an accurate 
description of three new pharmacophoric points: A4, H7 and H9, which are 
particularly important for a selective BACE inhibition.
The structural diversity of the compounds used in our study contributes 
to the value of our pharmacophore model, which is also substantiated by the 
X-ray structure of the binding conformation of compound 1, perfectly filling 
the seven pharmacophoric points.
The design of new BACE inhibitors has to consider the other human 
aspartic proteases which could be potentially inhibited by BACE ligands, 
such as renin, napsin-A, and B, cathepsin-E, pepsinogen-A, and C and 
cathepsin-D. Indeed, the catalytic domain of BACE is similar to that of 
other aspartyl proteases and the interactions of these enzymes with their 
inhibitors do not diverge too much from those we observed in the case of 
BACE. For instance, most of the human aspartyl proteases accept a 
phenylalanine analogue in P1. The selectivity versus BACE over other 
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human aspartic proteases is required to avoid adverse side effects and is thus 
mandatory for clinical development of BACE inhibitors. For instance, 
inhibition of cathepsin D, which is largely expressed in all cells controlling 
their protein catabolism,[35] would mean a likely consuming of that BACE 
inhibitor as well as the occurrence of probable toxicity.
Therefore we performed a structure-based sequence alignment of BACE 
and cathepsin D to investigate the differences in their binding sites (Table 
3).
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Table 3. Main dissimilarities in BACE and Cathepsin-D 
catalytic sites.
Binding Site 
Location
BACE residues
Cathepsin D 
residues
S2 Open Region
N233
R235
S325
S327
L236
V238
M307
M309
S1’ pocket K224 E227
Loop between S1’ 
and S2’
S328, T329 and 
G330
D310, I311, 
P312, P313, 
P314, S315, 
G316, P317 and 
L318
S2’ pocket R128 V144
Flap Region T72 G79
Others R307K321
L292
L303
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The superposition of BACE and cathepsin D three-dimensional 
structures reveals that the two enzymes display very similar residues in their 
binding sites and consequently possess a similar shape, which is visualised 
by their Connolly surfaces in Figure 8. In addition to the catalytic dyad, 
several residues important for the ligands recognition such as G34 or G230 
(G35 and G233 in cathepsin D) are conserved. As shown in Figure 8, the 
shape of the hydrophobic S1 and S2’ pockets is equivalent in BACE and 
cathepsin D. However, a careful comparison of the two binding sites reveals 
several important points of diversification (Figure 8).
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Figure 8. Superposition of BACE (pink) and cathepsin D (brown) structures 
represented as Connolly surfaces. The pharmacophoric points were mapped into the 
BACE enzyme. Mutated residues in the binding pocket are shown in stick 
representation and labelled with the one-letter amino acid code. The letters and the 
number in parentheses refer to the cathepsin D enzyme.
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Probably the most striking difference is located near to the catalytic 
dyad and thus easily accessible to the inhibitors; it concerns the S2 pocket, 
which presents the polar triplet N233-R235-S325 in BACE and the 
hydrophobic triplet L236-V238-M307 in cathepsin D. In line with this 
observation, a series of highly selective inhibitors containing a sulfonyl 
group in the P2 branch interacts with the residues of the BACE S2 
region.[27,29] Besides the different character of the S2 region in BACE and 
cathepsin D, the space available for the ligand binding in cathepsin D is 
limited by the M307 and M309 side chains; these are replaced by less space 
spacious residues in BACE (S325 and S327). This finding suggests the 
incorporation of bulky P2 branches, functionalized with polar groups 
capable to interact with the BACE triplet (N233-R235-S325).
The superposition of BACE and cathepsin D reveals significant 
differences in the length and sequence of the loop defining the S1’/S3’ 
pocket. Indeed, this loop is shorter in BACE (S327, S328, T329 and G330) 
than in cathepsin D, which presents a long loop of ten residues containing a 
rigid section called proline loop (P312, P313, P314, S315, G316 and P317).
This relevant difference indicates an alternative way to achieve 
BACE/cathepsin D selectivity. Indeed, a properly oriented bulky moiety on 
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the P1’ substituent will occupy the BACE S1’ pocket and will not be 
tolerated by cathepsin D. Moreover, the mutation of BACE-K224 in E227 in 
cathepsin D, suggests the insertion of an hydrogen bond acceptor or a 
positively charged group on the bulky moiety. To our knowledge, only few 
peptidic inhibitors targeted an interaction with K224.[15,18]
Another dissimilarity between BACE and cathepsin D resides in the S2’ 
pocket, where R128 is replaced by V144 in cathepsin D. Therefore, 
inhibitors including one or more acidic functions on the P2’ branch are 
expected to favour the interaction with BACE. The cathepsin D flap region, 
where G79 replaces the BACE-T72, offers another opportunity for 
enhancing the selectivity. The last divergence of BACE/cathepsin D resides 
in the region above the S3 pocket. Here, as shown in Figure 8, two basic 
amino acids (R307 and K321) are replaced by two hydrophobic residues 
(L292 and L303) in cathepsin D. Thus, compounds presenting an interaction 
with R307 and/or K321 (e.g. 4) may contribute to the selective BACE 
inhibition.
Mapping our pharmacophore model into the BACE/cathepsin D 
superposed structures, two main issues can be inferred. Firstly, it is apparent 
how the conserved pharmacophoric points (blue spheres in Figure 8) are 
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essential for the ligand recognition in both the enzymes. These 
pharmacophoric points are placed in a region where all residues are 
conserved, therefore these points cannot confer selectivity.
On the contrary, some additional points (cyan spheres in Figure 8) are 
located in regions, which are dissimilar in BACE and cathepsin D. In 
particular, the H/A8 has to be considered critical for the improvement of 
ligand potency and selectivity by allowing the interaction with the basic 
triplet (N233, R235 and S325) present in BACE and not in the homologous 
cathepsin D. Similarly, the H6 and H7 points both offer the opportunity to 
obtain compounds featuring an acidic groups or an H-bond acceptor on the 
P1’ and P2’ branches so as to allow an interaction with R128 and K224 
residues, which are only expressed in BACE.
In conclusion, despite the high sequence homology between BACE and 
cathepsin D, we have identified a distinctive fingerprint of the BACE 
catalytic site that is worth targeting in the effort to achieve potent and 
selective inhibitors.
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In the present paper an ensemble-docking approach was undertaken on six 
highly potent BACE inhibitors identifying for all of them plausible binding 
modes. A common pharmacophore model linking the multiple structural 
classes of inhibitors was derived. This allowed us to capture both the 
geometric and electronic features essential for the ligand recognition and the 
enzyme inhibition. In particular, we identified a nine points pharmacophore 
model outlining the relative distances among them. Interestingly, five of 
these points are present in all the inspected ligands; they can be referred to 
as essential features for the ligand recognition. Whereas the other four 
points have been defined as accessory points of interaction. An accurate 
structural comparison of BACE and cathepsin D was made to support the 
rational design of BACE-selective inhibitors. Despite the high degree of 
similarity, many structural differences were identified and highlighted; these 
can be used to achieve or enhance a selective BACE inhibition.
Both, the elucidation of the binding modes of the diverse ligands, and 
the development of an exhaustive structure-based pharmacophore model are 
expected to provide a support for pharmacophore- and structure-based VS 
techniques and a source for the optimization of screen derived hits as well as 
of established leads. Moreover, the pharmacophore hypotesis can be of help 
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in the common target-based and ligand-base drug design approaches as well 
as in the setting of a focused-library of BACE inhibitors.
Computational Methods
- 57 -
COMPUTATIONAL METHODS
Computational Methods
- 58 -
Molecular modeling calculations and graphics manipulations were 
performed on a Silicon Graphics Octane2 workstation equipped with two 
2600 MHz R14000 processors using the SYBYL7.2 software package.[36] 
Automated docking calculations were performed using version 3.0.5 of the 
AutoDock software package.[37]
The Docking Program.
AutoDock program combines a rapid energy evaluation through pre-
calculated grid maps of affinity potentials, one for each atom type present in 
the ligand being docked, with a variety of search algorithms to find suitable 
binding positions for a ligand on a given protein. While the protein is 
required to be rigid, the program allows torsional flexibility in the ligand. 
The calculation of these maps helps to make the docking process extremely 
fast. They are calculated by the AutoGrid procedure where the protein is 
embedded in a 3-D grid with a probe atom placed at each grid point. The 
interaction energy between the probe atom and the protein is computed for 
each grid point via a smoothed Lennard-Jones pairwise potential, with the 
effect of widening the region of maximum affinity at e, and also reducing 
the potential energy at r = 0 to a finite value (Figure 9):
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V(r) = cm,n e [(s/r)m - (s/r)n]
m and n are positive integer number and m > n (usually 12 and 6, 
respectively), e is the depth of the potential well and s is the finite distance 
at which the interparticle potential is zero. (1/r)m and (1/r)n describe 
repulsion and attraction terms, respectively. cm,n is chosen to get the 
minimum value of V(r) being Vmin = - e.
Figure 9. Comparison between the 
smoothed van der Waals potential used by 
AutoDock program and the classic 
unsmoothed van der Waals potential.
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As a result, an affinity grid is obtained for each atom type of the ligand 
as well as a grid of the electrostatic potential is calculated through
Coulombic interactions between the macromolecule and a point charge of 
+1.60219x10-19 C used as a probe (Figure 10), by means of the following 
equation:
F = 1/4pe(r) q1q2/r2
where e(r) is a sigmoidal distance-dependent dielectric function used to 
model solvent screening, q1 and q2 are the charge values of the probe and 
the corresponding atom of the macromolecule and r is the distance between 
q1 and q2.
The energetic profile of a particular substrate configuration is eventually 
found by counting both the affinity values and the electrostatic interactions 
of the grid points surrounding each atom of the given ligand.
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Figure 10. Graphical exemplification of the grid points used by 
AutoGrid to calculate protein maps.
The scoring function of AutoDock was parameterized using a series of 
protein-inhibitor complexes for which both the structures and the inhibition 
constant, Ki, are known. Looking at the theory, AutoDock scoring function 
is based on the Hess’s law of heat summation. This law states that since the
free energy is a state function, the change in the free energy between two 
states will be the same regardless of what pathway is taken to achieve the 
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products. So the calculation of the free energy of binding in solvent can be 
expressed by the following equation:
DGbinding solution = DGbinding vacuo + DGsolvation(EI) - DGsolvation(E+I)
since DGbinding vacuo can be calculated by the docking simulation, and we can 
also estimate the solvation free energy for the complex (EI) and for the 
separate inhibitor (I) and protein (E), we eventually are able to calculate the 
free energy change upon binding of the ligand to the protein in solution, 
DGbinding solution, and the corresponding inhibition constant, Ki.
Ligand setup.
The protonation state of ligands 1-6 was calculated using MarvinSketch 
tools (available at http://www.chemaxon.com/marvin/doc/dev/example-
sketch1.1.html) at the pH value of the corresponding biological essay. The 
absolute stereochemistry of each ligand was considered as reported in 
literature. Due to the undetermined stereochemistry on the N-terminal 
hydroxyl group of compound 2, both possible isomers were taken into 
account for the docking calculations. For 2, 3 and 4 the Cambridge 
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Structural Database (CSD)[38] was searched for the conformational 
preference of the cyclohexyl and the piperazinone moieties. Energy 
minimizations of the obtained structures were achieved with the TRIPOS 
force field using the SYBYL/MAXIMIN2 minimizer by applying the BFGS 
(Broyden, Fletcher, Goldfarb and Shannon) algorithm[39] with a 
convergence criterion of 0.001 kcal/mol. Partial atomic charges were 
assigned by using the Gasteiger-Marsili formalism.[40] All the relevant 
torsion angles were treated as rotatable during the docking process, allowing 
thus a search of the conformational space.
Protein setup.
All the X-ray structures of BACE (PDB entry codes = 1FKN, 1W51, 
1TQF, 1XN3 and 2G94)[13,26-29] were set up for docking as follows: polar 
hydrogens were added using the BIOPOLYMERS module of the SYBYL 
program (the side chain of Asp32 was taken as protonated[24,41] while all 
other Asp, Glu, Lys and Arg side chains were considered ionized and all His 
were considered neutral by default), Kollman united-atom partial charges 
were assigned and all waters were removed. In order to optimize the side 
chains and the hydrogen positions, the protein structures were minimized 
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using both steepest descent and conjugate gradient, keeping the backbone 
atoms constrained, employing the DISCOVER program with the CVFF 
force field.[42] ADDSOL utility of AutoDock program was used to add 
salvation parameters to the protein structures and the grid maps representing 
the proteins in the docking process were calculated using AutoGrid. The 
grids, one for each atom type in the ligand, plus one for electrostatic
interactions, were chosen to be large enough to include not only the catalytic 
site, but also a significant part of the protein around it. As a consequence, 
for all docking calculations, the dimensions of grids map was 60 x 60 x 60 
• with a grid -point spacing of 0.375 •. The centre of the grid was set to be 
coincident with one of the two oxygens of Asp228.
Docking simulation.
For each ligand, 100 separate docking calculations were performed. 
Each docking calculation consisted of 1×106 energy evaluations using the 
Lamarckian genetic algorithm local search (GALS) method. A low-
frequency local search according to the method of Solis and Wets is applied 
to docking trials to ensure that the final solution represents a local 
minimum. Each docking run was performed with a population size of 150, 
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and 300 rounds of Solis and Wets local search were applied with a 
probability of 0.06. A mutation rate of 0.02, a crossover rate of 0.8 and an 
elitism value of 1 were used to generate new docking trials for subsequent 
generations. The GALS method evaluates a population of possible docking 
solutions and propagates the most successful individuals from each 
generation into the next one. The docking results from each of the 100 
calculations were clustered on the basis of root-mean square deviation (rmsd 
= 2 Å) between the Cartesian coordinates of the ligand atoms and were 
ranked on the basis of the free energy of binding.
The result with the lowest free energy of binding was taken as the 
representative of each cluster.
Energy refinement of the BACE-1/ligand complexes.
Energy optimizations of the obtained complexes were carried out using 
3000 steps of steepest descent followed by 2000 steps of conjugated 
gradient algorithm with employing the CVFF force field as implemented in 
the DISCOVER program.[42] A convergence criterion on the gradient of 
0.001 kcal mol-1 Å-1 was set. Only the ligand and the side chains of all 
residues within a radius of 8 Å around the ligand were allowed to relax.
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Connolly surfaces of BACE and cathepsin D were calculated using 
PyMOL software.[43]
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